Table 4.

Results of ANCOVA models with composite cognitive scores as the outcome variable, cholesterol Qs as independent variables stratified by homocysteine^a

Homocysteine	Cholesterol	Total cohort (N=1,889)			Sub-sample (N=1,700)b
		Estimation	SE	P-value	Estimation	SE	P-value
Q1 (≤11.81 μmol/L)	Q1 (≤125.26 mg/dL)	−0.18	0.08	0.0208*	−0.19	0.07	0.0063*
	Q2 (125.26, 154.25 mg/dL)	−0.08	0.08	0.3078	−0.03	0.07	0.6506
	Q3 (154.25, 186.73 mg/dL)	0.20	0.08	0.0146*	0.15	0.07	0.0342
	Q4 (>186.73 mg/dL)	Reference	–	–	Reference	–	–
Q2 (11.81, 15.25 μmol/L)	Q1 (≤125.26 mg/dL)	−0.16	0.08	0.0355*	−0.10	0.07	0.1342
	Q2 (125.26, 154.25 mg/dL)	−0.15	0.08	0.0506	−0.07	0.07	0.2960
	Q3 (154.25, 186.73 mg/dL)	0.01	0.08	0.8820	0.06	0.07	0.3653
	Q4 (>186.73 mg/dL)	Reference	–	–	Reference	–	–
Q3 (15.25, 20.12 μmol/L)	Q1 (≤125.26 mg/dL)	−0.22	0.08	0.0063*	−0.23	0.07	0.0017*
	Q2 (125.26, 154.25 mg/dL)	−0.06	0.07	0.4055	−0.13	0.07	0.0490
	Q3 (154.25, 186.73 mg/dL)	0.00	0.07	0.9613	−0.05	0.07	0.4076
	Q4 (>186.73 mg/dL)	Reference	–	–	Reference	–	–
Q4 (>20.12 μmol/L)	Q1 (≤125.26 mg/dL)	−0.06	0.08	0.4372	−0.05	0.07	0.4335
	Q2 (125.26, 154.25 mg/dL)	0.06	0.09	0.5061	0.00	0.07	0.9747
	Q3 (154.25, 186.73 mg/dL)	−0.05	0.08	0.5209	−0.02	0.06	0.7252
	Q4 (>186.73 mg/dL)	Reference	–	–	Reference	–	–
Normal homocysteine (≤14 μmol/L)	Q1 (≤125.26 mg/dL)	−0.17	0.06	0.0050	−0.14	0.05	0.0103
	Q2 (125.26, 154.25 mg/dL)	−0.09	0.06	0.1219	−0.02	0.05	0.6965
	Q3 (154.25, 186.73 mg/dL)	0.12	0.06	0.0411	0.12	0.05	0.0220
	Q4 (>186.73 mg/dL)	Reference	–	–	Reference	–	–

Notes:

^aAll models were adjusted for age, sex, years of education, smoking status, body mass index, and history of heart disease.

^bExcluding participants in the bottom 10% of composite cognitive scores.

^*Statistically significant values.

Abbreviations: ANCOVA, analysis of covariance; N, number of participants; Q, quartile group; SE, standard error.